Diligence memo · auto-generated · as of July 2, 2026
BlueWhale Bio, Inc.
BlueWhale Bio, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
BlueWhale Bio, Inc. operates in Biotechnology, based in PHILADELPHIA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
BlueWhale Bio, Inc. has raised $5.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.0M on 2025-10-10.
Most recent recorded round closed around 2025-10-10.
Valuation (modeled)modeled
Provath models BlueWhale Bio, Inc. at approximately $14M (range $5.5M–$23M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.91× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era. Within the normal band (91% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 9 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 44% of Biotechnology peers (4293 compared).
Modeled value ranks above 24% of those peers.
Closest niche peers: Acasti Pharma Inc., Edesa Biotech, Inc., 4DMedical Ltd, Arialys Therapeutics, Inc., Nuclein, LLC.
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.